Investors on Alert: Class Action Lawsuit Filed Against Soleno Therapeutics for Alleged Securities Fraud

Investor Warning: Class Action Against Soleno Therapeutics

Pomerantz LLP, a well-respected law firm specializing in securities litigation, is raising awareness among investors who have experienced losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO). The firm has announced the initiation of a class action lawsuit against Soleno, a company that has recently faced scrutiny over its business practices and the safety of its primary product.

Background of the Lawsuit

The class action alleges that Soleno and certain executives may have engaged in fraudulent activities that misled investors. Specifically, the lawsuit arises from critical reports published by Scorpion Capital, which raised concerns over Soleno's product, diazoxide choline extended-release tablets (DCCR), branding it as overpriced and potentially harmful, especially for pediatric patients. Following the release of this report on August 15, 2025, Soleno's stock suffered a significant drop, closing at $71.63 with a loss of 7.41%.

The situation escalated when a tragic incident was reported, involving the death of a patient under treatment with DCCR. This announcement, made on September 10, 2025, precipitated another steep decline, with shares plummeting by 19.21% to finish at $56.72. Further revelations during Soleno’s quarterly earnings call on November 4, 2025, indicated a troubling 8% discontinuation rate for the medication linked to adverse effects. These compounded issues resulted in the stock closing at $46.87, a decrease of 26.59% in the immediate aftermath of the financial report.

Calling on Affected Investors

Investors who acquired Soleno shares during this tumultuous period are urged to act swiftly. The deadline for those interested in joining the class action as Lead Plaintiff is May 5, 2026. Interested parties should reach out to Danielle Peyton, an attorney at Pomerantz, for more information. Contact can be made via email at [email protected] or by phone at 646-581-9980. When reaching out, it is beneficial for investors to provide details of their investment, including the number of shares purchased, contact information, and their mailing address.

The Role of Pomerantz LLP

With a storied history of over 85 years, Pomerantz LLP is recognized as a leading firm in corporate and securities class action lawsuits. Founded by the late Abraham L. Pomerantz, known as the “dean of the class action bar,” the firm has a track record for successfully advocating for those who have suffered from securities fraud and corporate misconduct. Their dedicated approach aims to ensure that wronged investors are compensated justly.

Conclusion

This lawsuit underscores the importance of vigilance for investors in the biotech sector. Allegations of securities fraud not only impact stock prices but also shake investor confidence. As the case progresses, Pomerantz LLP remains committed to pursuing justice for those affected by Soleno’s actions. Investors are encouraged to stay informed and act promptly to safeguard their interests.